Literature DB >> 21607559

Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course.

Mara Anaís Llamas-Covarrubias1, Yeminia Valle, Rosa Elena Navarro-Hernández, Iris Paola Guzmán-Guzmán, María Guadalupe Ramírez-Dueñas, Héctor Rangel-Villalobos, Ciro Estrada-Chávez, José Francisco Muñoz-Valle.   

Abstract

Rheumatoid arthritis (RA) is an inflammatory autoimmune disease of unknown etiology. Many cytokines have been found to be associated with RA pathogenesis and among them is macrophage migration inhibitory factor (MIF). The aim of this study was to determine whether MIF serum levels are associated with RA course, clinical activity, and clinical biomarkers of the disease. MIF levels were determined in serum samples of 54 RA patients and 78 healthy subjects (HS) by enzyme-linked immunosorbent assay (ELISA). Disease activity was evaluated using the DAS28 score. Patients were subgrouped according to disease activity and years of evolution of disease. Statistical analysis was carried out by SPSS 10.0 and GraphPad Prism 5 software. RA patients presented increased levels of MIF as compared to HS. MIF levels were raised on early stages of RA and tend to decrease according to years of evolution. Moreover, MIF levels positively correlated with rheumatoid factor in RA patients and with C reactive protein in all individuals studied. Our findings suggest that MIF plays a role in early stages of RA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21607559     DOI: 10.1007/s00296-011-1951-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  19 in total

1.  Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis.

Authors:  M Leech; C Metz; L Santos; T Peng; S R Holdsworth; R Bucala; E F Morand
Journal:  Arthritis Rheum       Date:  1998-05

2.  The effects of macrophage migratory inhibitory factor on acute-phase protein production in primary human hepatocytes.

Authors:  Nicholas M Wheelhouse; Nabil Dowidar; Cornelis H C Dejong; O James Garden; James J Powell; Matthew D Barber; Kathryn Sangster; Jean P Maingay; James A Ross
Journal:  Int J Mol Med       Date:  2006-11       Impact factor: 4.101

3.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

4.  An essential regulatory role for macrophage migration inhibitory factor in T-cell activation.

Authors:  M Bacher; C N Metz; T Calandra; K Mayer; J Chesney; M Lohoff; D Gemsa; T Donnelly; R Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

5.  A novel DNA vaccine targeting macrophage migration inhibitory factor protects joints from inflammation and destruction in murine models of arthritis.

Authors:  Shin Onodera; Shigeki Ohshima; Harukazu Tohyama; Kazunori Yasuda; Jun Nishihira; Yoichiro Iwakura; Ikkei Matsuda; Akio Minami; Yoshikazu Koyama
Journal:  Arthritis Rheum       Date:  2007-02

6.  Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis.

Authors:  M Leech; C Metz; R Bucala; E F Morand
Journal:  Arthritis Rheum       Date:  2000-04

Review 7.  Macrophage migration inhibitory factor and its role in autoimmune diseases.

Authors:  Claudia M Denkinger; Christine Metz; Günter Fingerle-Rowson; Michael D Denkinger; Thomas Forsthuber
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2004 Nov-Dec       Impact factor: 4.291

Review 8.  Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis.

Authors:  Leilani L Santos; Eric F Morand
Journal:  Clin Chim Acta       Date:  2008-09-21       Impact factor: 3.786

9.  Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

Authors:  N Nishimoto; N Miyasaka; K Yamamoto; S Kawai; T Takeuchi; J Azuma
Journal:  Ann Rheum Dis       Date:  2008-11-19       Impact factor: 19.103

10.  Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project.

Authors:  Kylie Thaler; Divya V Chandiramani; Richard A Hansen; Gerald Gartlehner
Journal:  Biologics       Date:  2009-12-29
View more
  16 in total

1.  Serum macrophage migration inhibitory factor is correlated with atrial fibrillation.

Authors:  Chunfu Wan; Zhihua Li
Journal:  J Clin Lab Anal       Date:  2017-04-13       Impact factor: 2.352

2.  MIF, a potential therapeutic target for rheumatoid arthritis?

Authors:  Zhaolin Chen; Taotao Ma; Cheng Huang; Lei Zhang; Tingting Hu; Jun Li
Journal:  Rheumatol Int       Date:  2014-01-25       Impact factor: 2.631

3.  Macrophage migration inhibitory factor as a novel biomarker of portopulmonary hypertension.

Authors:  Hilary M DuBrock; Josanna M Rodriguez-Lopez; Barbara L LeVarge; Michael P Curry; Paul A VanderLaan; Zsuzsanna K Zsengeller; Elizabeth Pernicone; Ioana R Preston; Paul B Yu; Ivana Nikolic; Dihua Xu; Ravi I Thadhani; Richard N Channick; S Ananth Karumanchi
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

4.  Macrophage Migration Inhibitory Factor -173GC Variant Might Increase the Risk of Behçet's Disease.

Authors:  Ayse Feyda Nursal; Serbulent Yigit; Ercan Tural; Goknur Kalkan; Mehmet Kemal Tumer; Akin Tekcan
Journal:  Med Princ Pract       Date:  2018-04-18       Impact factor: 1.927

5.  Macrophage migration inhibitory factor (MIF) promoter polymorphisms (-794 CATT5-8 and -173 G>C): association with MIF and TNFα in psoriatic arthritis.

Authors:  Ramsés Morales-Zambrano; Luis A Bautista-Herrera; Ulises De la Cruz-Mosso; Guadalupe D Villanueva-Quintero; Jorge R Padilla-Gutiérrez; Yeminia Valle; Isela Parra-Rojas; Héctor Rangel-Villalobos; Sergio R Gutiérrez-Ureña; José F Muñoz-Valle
Journal:  Int J Clin Exp Med       Date:  2014-09-15

6.  Association of Macrophage Migration Inhibitory Factor Gene -173 G/C Polymorphism (rs755622) with Familial Mediterranean Fever in Children.

Authors:  Nursen Cakan; Resul Yılmaz; Erhan Karaaslan; Ömer Ateş
Journal:  J Pediatr Genet       Date:  2020-11-25

7.  Macrophage migration inhibitory factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis.

Authors:  M A Llamas-Covarrubias; Y Valle; R Bucala; R E Navarro-Hernández; C A Palafox-Sánchez; J R Padilla-Gutiérrez; I Parra-Rojas; A G Bernard-Medina; Z Reyes-Castillo; J F Muñoz-Valle
Journal:  Cytokine       Date:  2013-02-09       Impact factor: 3.861

8.  Macrophage migration inhibitory factor: association of -794 CATT5-8 and -173 G>C polymorphisms with TNF-α in systemic lupus erythematosus.

Authors:  U De la Cruz-Mosso; R Bucala; C A Palafox-Sánchez; I Parra-Rojas; J R Padilla-Gutiérrez; A L Pereira-Suárez; H Rangel-Villalobos; M Vázquez-Villamar; L I Angel-Chávez; J F Muñoz-Valle
Journal:  Hum Immunol       Date:  2014-02-12       Impact factor: 2.850

9.  Expression of MIF and TNFA in psoriatic arthritis: relationship with Th1/Th2/Th17 cytokine profiles and clinical variables.

Authors:  L A Bautista-Herrera; U De la Cruz-Mosso; R Morales-Zambrano; G D Villanueva-Quintero; J Hernández-Bello; M G Ramírez-Dueñas; E Martínez-López; L M Brennan-Bourdon; C J Baños-Hernández; J F Muñoz-Valle
Journal:  Clin Exp Med       Date:  2017-09-30       Impact factor: 3.984

10.  Macrophage migration inhibitory factor promoter polymorphisms (-794 CATT 5-8 and -173 G>C): relationship with mRNA expression and soluble MIF levels in young obese subjects.

Authors:  Inés Matia-García; Lorenzo Salgado-Goytia; José F Muñoz-Valle; Samuel García-Arellano; Jorge Hernández-Bello; Aralia B Salgado-Bernabé; Isela Parra-Rojas
Journal:  Dis Markers       Date:  2015-04-20       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.